Innovations In Clinical Neuroscience

Hot Topics in Pain Management October 2017

A peer-reviewed, evidence-based journal for clinicians in the field of neuroscience

Issue link: https://innovationscns.epubxp.com/i/895375

Contents of this Issue

Navigation

Page 11 of 21

12 Hot Topics in Pain Management [October 2017] MEETING HIGHLIGHTS estimation using multi-modal data from wearable sensors" (poster #340), which evaluated a novel pain intensity estimation method that uses multi-modal data from a wrist-worn sensor. They reported that their algorithm demonstrated robustness in a single-center, comparative, randomized, crossover, clinical study that evaluated the impact of different injection parameters on subcutaneous injection pain tolerance. * More information PEDIATRIC PAIN MANAGEMENT Hainsworth et al presented, "The role of inflammatory biomarkers in youth with co-occurring chronic pain and obesity" (poster #247), which examined relationships between body weight and pain status, serum biomarker concentrations, and measures of physical and emotional functioning in a cohort of adolescents who had chronic pain or depression, chronic pain and depression, or had neither. Based on their results, the investigators surmised that cytokine concentrations are differentially affected by the co-occurrence of chronic pain and obesity, as compared with the effects associated with either condition alone. * More information Hatfield and Umberger presented the results of their study, "The association between parental education/knowledge of genetics and parental attitudes in genotypic pediatric pain research" (poster #255). Here, the investigators examined the association between parental education/knowledge of genetics and parental willingness to enroll their children in genotypic pediatric pain research. The presenters found that education is not a significant factor in decisions made by parents to enroll their children in genotypic pain research. In fact, education/genetic knowledge might actually result in a reluctance to participate in genomic research. * More information Wan et al presented the results of their study, "Pain as a predictor of persistent post concussion symptoms in adolescents" (poster #413), which examined whether pain and sleep duration predicted persistent post-concussion symptoms in adolescents. The presenters reported that early symptoms of pain might be associated with higher severity of post-concussion symptoms after the expected recovery period. They concluded that addressing pain symptoms early on following a concussion might minimize the development of persistent symptoms. * More information MIGRAINE Nahman-Averbuch et al presented results from their study, "Meta- analysis confirms modality and location specific alterations in pain thresholds in migraine patients" (poster #369). Here, the investigators sought to determine if there were differences in pain thresholds between migraine patients and healthy controls, and if such differences vary according to stimulus modality and stimulus location. They reported that the alterations in nociceptive processing of migraine patients are modality- and location-specific. The investigators concluded that symptoms associated with pressure sensations are often reported during migraine attack, and sensory abnormalities appear to be somatopically localized to the head and neck areas and do not appear to indicate a pattern of generalized sensitization. O'Neal et al compared Trokendi XR® (extended-release topiramate), a novel, extended-release formulation producing more constant steady-state TPM plasma concentration-time profile with QD dosing, to TPM-immediate release (IR) with BID dosing in patients with chronic migraines. Their study, "Cognitive tolerability and health outcomes with once-daily Trokendi XR® (extended-release topiramate) in migraineurs" (poster #370) demonstrated significantly greater adherence (p<0.001), longer persistence (p<0.001), and higher continuation rates (p<0.001) among study subject taking Trokendi XR compared to those taking TPM-IR. In patients treated continuously for six months or longer, the investigators reported that differences in monthly migraine events, migraine-related outpatient visits, prescriptions for migraine-related drugs, and all- cause healthcare use significantly (p<0.001) favored Trokendi XR. Mark Your Calendars! The American Pain Society 37 th Annual Scientific Summit March 4–6, 2018 Annaheim, California www.americanpainsociety.org

Articles in this issue

Links on this page

Archives of this issue

view archives of Innovations In Clinical Neuroscience - Hot Topics in Pain Management October 2017